Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04333225 · ClinicalTrials.gov registry record · Phase 2
Hydroxychloroquine in the Prevention of COVID-19 Infection in Healthcare Workers
A Phase 2 study, sponsored by Baylor Research Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 221
- Enrollment target
NCT04333225 is a Phase 2 study that has completed, run by Baylor Research Institute. The registered enrollment target is 221 participants.
The verdict
NCT04333225, a Phase 2 study, has completed, sponsored by Baylor Research Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 221 participants
- Enrollment target
Study Summary
In order to assess the efficacy of hydroxychloroquine treatment weekly for a total of 7 weeks in the prevention of COVID-19 infection, three hundred sixty (360) Healthcare workers with high risk exposure to patients infected with COVID-19 will be tested for COVID-19 infection via nasopharyngeal (NP) swab once weekly for 7 weeks. Of those, one hundred eighty (180) will receive weekly doses of hydroxychloroquine for the duration of the study. Subjects who opt not to receive the study drug will form the control group.
Interventions
- DRUG Hydroxychloroquine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 221 participants |
| Start Date | 2020-04-03 |
| Est. Completion | 2020-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04333225
The ClinicalTrials.gov registry entry for NCT04333225 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 221 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baylor Research Institute, which has 180 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Hydroxychloroquine is the first listed.
NCT04333225 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04333225 about?
NCT04333225 is a clinical study titled "Hydroxychloroquine in the Prevention of COVID-19 Infection in Healthcare Workers". In order to assess the efficacy of hydroxychloroquine treatment weekly for a total of 7 weeks in the prevention of COVID-19 infection, three hundred sixty (360) Healthcare workers with high risk exposure to patients infected with COVID-19 will be tested for COVID-19 infection via nasopharyngeal (NP)...
What is the current status of trial NCT04333225?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 221 participants. The study started on 2020-04-03. Estimated completion is 2020-06-30.
What interventions are being tested in trial NCT04333225?
The interventions under investigation include: Hydroxychloroquine (DRUG).
Who is sponsoring clinical trial NCT04333225?
This trial is sponsored by Baylor Research Institute, which has 180 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.